Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5152W HIGH $59.70
Volume
22.40 M
Value Traded
33.48 K
Short % Float
1.85%
+71.95%Week
+206.52%1 Month
-4.08%3 Month
-76.5%6 Month
-62.5%5 Year
-62.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.64 M
EPS (TTM)
-38.55
P/E Ratio
-
Ent. Value
10.36 M
Total Shares
1.51 M
Float Shares
560.00 K
Insiders
62.68%
Institutions
2.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
APUS Catalyst Timeline
Dated clinical, regulatory and corporate events for Apimeds Pharmaceuticals US, Inc.
Past FDA Catalysts and PDUFA Decisions
How APUS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F9 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 100%
Micro Cap(rank 658 of 658)
Percentile Rank
Apimeds Pharmaceuticals US, Inc. has significant pipeline risk (9/100), with 1 assets in development, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every APUS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kim ChristopherDirector, Officer (Chairman and CMO) | Buy | 7,730 27,500 held | $1.86 | 05/14/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in APUS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in APUS for Q2 2026. | ||||
APUS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How APUS ranks across every disease it competes in
Competitive Position is a premium feature
See how APUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAPUS News
APUS▲ +57.9%on this news
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
Apimeds Pharmaceuticals US has settled with Inscobee, allowing the merger with MindWave Innovations to proceed. The settlement also facilitates a $100 million PIPE financing and the advancement of Lōkahi Therapeutics' Apitox program. Trading of APUS stock is expected to resume on May 5, 2026.
Read more →APUS▲ +59.6%on this news
Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual Report
Apimeds Pharmaceuticals announced it received a notice of non-compliance from NYSE Regulation regarding the late filing of its Form 10-K for the fiscal year ending December 31, 2025. The company is under scrutiny to complete its filing by April 30, 2026, following which the trading of its stock is designated with a '.LF' for late filings. Should the company fail to correct this within the specified periods, it risks suspension or delisting from the exchange.
Read more →APUSInscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
Inscobee Inc. and Apimeds, Inc. have announced the removal of several board members and the appointment of new directors for Apimeds Pharmaceuticals US, Inc. This change follows a Written Consent delivered by stockholders holding a majority of voting power. MindWave Innovations has challenged these actions, alleging breaches of a Support Agreement, which the companies strongly deny.
Read more →APUS▼ -12.3%on this news· ran to -90% by day 3shared move
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
Apimeds Pharmaceuticals US Inc. (APUS) has announced a material breach of its merger agreement by Inscobee Inc. and its subsidiary, which initiated a hostile takeover in violation of their contractual commitments. Inscobee claims to have removed the company's board without authorization, prompting APUS to prepare an emergency legal action in Delaware to contest the changes and maintain its board structure. The company is also engaging legal counsel in Korea to address Inscobee's actions under both U.S. and Korean law. APUS emphasizes its intention to defend shareholder interests and fulfill its merger objectives.
Read more →APUS▼ -24.1%on this news
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
Apimeds Pharmaceuticals and Lōkahi Therapeutics announced a Type C meeting with the FDA to discuss LT-100, a biologic candidate for osteoarthritis treatment. This meeting, scheduled for May 4, 2026, aims to align on development strategies for the product, which is based on honeybee venom and has been previously approved in South Korea. The companies are enhancing the manufacturing process and integrating historical data to support its advancement in the U.S.
Read more →APUSApimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
Apimeds Pharmaceuticals has successfully closed a $100 million PIPE financing, enhancing its financial standing and advancing its non-opioid therapeutic programs. The integration with MindWave Innovations will streamline operations and financial management. Additionally, the transfer of 1,000 Bitcoin into a risk-managed structure aims to generate returns while preserving capital.
Read more →APUSApimeds and MindWave Announce Merger, Integrating
Apimeds Pharmaceuticals has announced a merger with MindWave Innovations, combining their expertise in biotechnology and digital asset treasury solutions. The merger, accompanied by a concurrent PIPE financing of $100 million, aims to enhance Apimeds' clinical programs while expanding MindWave's digital asset infrastructure. This strategic alliance intends to capitalize on both companies' strengths, positioning them in rapidly growing sectors. However, potential integration issues and market volatility remain as risks.
Read more →APUS▲ +12.9%on this news
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
Apimeds Pharmaceuticals has announced a collaboration with the University of Idaho to expand its ai² Futures Lab program, starting in Spring 2026. This initiative will connect students with real-world biopharma projects, enhancing their education and fostering innovation. The partnership aims to prepare students for leadership roles in biotechnology and healthcare.
Read more →APUSApimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
Apimeds Pharmaceuticals has expanded its ai² Futures Lab program through a collaboration with the University of Oregon's Lundquist College of Business. Starting in Winter 2026, this initiative will connect students with biopharma business development projects, allowing them to work on real pharmaceutical assets. The partnership aims to foster innovation and prepare students for careers in the industry.
Read more →APUS▼ -5.9%on this news
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
Apimeds Pharmaceuticals has expanded its ai² Future Labs program to include graduate students from the University of San Diego's Knauss School of Business. This initiative aims to connect students with real-world biopharmaceutical projects, enhancing their skills in market analysis and drug development. The collaboration also provides students with potential internship opportunities at Apimeds.
Read more →APUS▲ +7.2%on this newsshared move
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
Apimeds Pharmaceuticals has welcomed the FDA's draft guidance on non-opioid pain therapies, which could expedite the development of its lead program, Apitox, for chronic osteoarthritis pain. The guidance allows for more flexible trial requirements and the possibility of faster regulatory pathways. This represents a significant opportunity for Apimeds to enhance its product's development timeline and improve patient outcomes.
Read more →APUSApimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Apimeds Pharmaceuticals has announced the expansion of its leadership team with the appointments of Dr. Susan Kramer as Senior Vice President of Development and Brian Peters as Head of its ai² division. Dr. Kramer, who has extensive experience in biopharmaceutical research, will oversee product development activities, while Peters will focus on strategic positioning and the launch of the ai² platform. These additions are seen as strengthening operational leadership at an important time for the company's Apitox program, a bee venom-based therapeutic being developed for osteoarthritis knee pain treatment.
Read more →APUSApimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Apimeds Pharmaceuticals US, Inc. has successfully closed its initial public offering, raising $13.5 million by selling 3,375,000 shares at $4.00 each. The funds will be used to support a Phase III clinical trial for knee osteoarthritis and other corporate initiatives. The shares began trading on the NYSE American under the ticker APUS on May 9, 2025.
Read more →APUSApimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Apimeds Pharmaceuticals US, Inc. has announced the pricing of its initial public offering, offering 3,375,000 shares at $4.00 each, aiming to raise $13.5 million. The funds will support a Phase III clinical trial for knee osteoarthritis and other studies. The offering is set to close on May 12, 2025, with shares trading on NYSE American starting May 9, 2025.
Read more →About Apimeds Pharmaceuticals US, Inc.
Headquarters100 MATAWAN RD, MATAWAN, NJ, 07747
BIOPHARMAWATCH ELITE PLUS
Trade the next APUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime